• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症相关临床试验中的假阳性心脏毒性事件:与非侵入性参数不完善相关的风险。

False Positive Cardiotoxicity Events in Cancer-Related Clinical Trials: Risks Related to Imperfect Noninvasive Parameters.

机构信息

Department of Cardiology, Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,

Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

出版信息

Chemotherapy. 2018;63(6):324-329. doi: 10.1159/000495147. Epub 2019 Mar 7.

DOI:10.1159/000495147
PMID:30844801
Abstract

PURPOSE

Cardiac ultrasound provides important structural and functional information that makes identification of cardiac abnormalities possible. Left ventricular ejection fraction (LVEF) provides the most commonly used parameter for recognition of treatment-related cardiac dysfunction. Random reading variance and physiologic factors influence LVEF and make the reported value imperfect. We attempt to quantitate the likelihood of false positive events by computer simulation.

METHODS

We simulated four visits on hypothetical trials. We assumed a baseline LVEF of 55% and normal distribution with regard to reading error and physiologic variation. 1,000 trials of sample size 1,500 were simulated. In a separate simulation, 1,000 patients entered with LVEFs of 45, 43, and 41% to estimate true positive incidence.

RESULTS

At each examination, less than 1.0% of false positives were noted. The cumulative false positive rate over four visits was 3.60%. True cardiotoxicity identification is satisfactory only when LVEF declines substantially.

CONCLUSION

A 3.60% false positive rate in trials where the expected level of toxicity is low suggests that false positives are troubling and may exceed true positive results. Strategies to reduce the number of false positive results include making confirmatory studies mandatory. Evaluating increases along with decreases obtains some estimation of variance.

摘要

目的

心脏超声提供了重要的结构和功能信息,使得心脏异常的识别成为可能。左心室射血分数(LVEF)提供了最常用的参数,用于识别与治疗相关的心脏功能障碍。随机读数的差异和生理因素会影响 LVEF,并使报告的值不完美。我们试图通过计算机模拟来量化假阳性事件的可能性。

方法

我们在假设的试验中模拟了四次就诊。我们假设基线 LVEF 为 55%,并且在读取误差和生理变化方面呈正态分布。模拟了样本量为 1500 的 1000 次试验。在另一个模拟中,有 1000 名患者以 45%、43%和 41%的 LVEF 进入,以估计真正的阳性发生率。

结果

每次检查时,假阳性的比例不到 1.0%。四次就诊的累积假阳性率为 3.60%。只有当 LVEF 显著下降时,才能准确识别心脏毒性。

结论

在毒性预期水平较低的试验中,假阳性率为 3.60%,这表明假阳性令人困扰,可能超过真正的阳性结果。减少假阳性结果数量的策略包括强制进行确认性研究。评估增加和减少可以获得一些方差的估计。

相似文献

1
False Positive Cardiotoxicity Events in Cancer-Related Clinical Trials: Risks Related to Imperfect Noninvasive Parameters.癌症相关临床试验中的假阳性心脏毒性事件:与非侵入性参数不完善相关的风险。
Chemotherapy. 2018;63(6):324-329. doi: 10.1159/000495147. Epub 2019 Mar 7.
2
Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process.心肌层变形分析可检测骨髓移植患者化疗后早期心功能障碍:一种连续且累加性的心脏毒性过程。
J Am Soc Echocardiogr. 2017 Nov;30(11):1091-1102. doi: 10.1016/j.echo.2017.07.010. Epub 2017 Aug 30.
3
Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer.三维超声心动图左心室射血分数对乳腺癌患者心脏毒性发病的检测可靠性。
J Am Soc Echocardiogr. 2017 Nov;30(11):1103-1110. doi: 10.1016/j.echo.2017.06.025. Epub 2017 Aug 16.
4
Potential usefulness of diastolic parameters measured by strain imaging echocardiography in the early prediction of chemotherapy-induced cardiotoxicity.应变成像超声心动图测量的舒张参数在化疗诱导的心脏毒性早期预测中的潜在效用。
Med Hypotheses. 2017 Apr;101:30-32. doi: 10.1016/j.mehy.2017.02.004. Epub 2017 Feb 10.
5
Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy.最新的超声心动图技术用于检测化疗期间的心毒性和心力衰竭。
Heart Fail Clin. 2011 Jul;7(3):313-21. doi: 10.1016/j.hfc.2011.03.003.
6
High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.高敏 C 反应蛋白(hs-CRP)作为曲妥珠单抗致 HER2 阳性早期乳腺癌心脏毒性的生物标志物:一项初步研究。
Breast Cancer Res Treat. 2012 Jul;134(1):291-8. doi: 10.1007/s10549-012-2039-z. Epub 2012 Apr 4.
7
Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.蒽环类药物化疗后早期肌钙蛋白I释放预测乳腺癌患者左心室收缩功能障碍
J Ayub Med Coll Abbottabad. 2017 Apr-Jun;29(2):266-269.
8
Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.曲妥珠单抗相关的心脏毒性:对可逆性概念提出质疑。
J Clin Oncol. 2007 Aug 10;25(23):3525-33. doi: 10.1200/JCO.2007.11.0106.
9
Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.左心室舒张末期容积作为HER2阳性乳腺癌患者曲妥珠单抗相关心脏毒性的早期指标:一项单中心回顾性研究的结果
Minerva Cardioangiol. 2017 Jun;65(3):278-287. doi: 10.23736/S0026-4725.16.04278-X. Epub 2016 Nov 25.
10
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.拉帕替尼的心脏安全性:对3689例参加临床试验患者的汇总分析
Mayo Clin Proc. 2008 Jun;83(6):679-86. doi: 10.4065/83.6.679.

引用本文的文献

1
Is the pendulum slowly starting to swing back?钟摆是否正在慢慢开始摆回来?
Cardiooncology. 2025 Feb 27;11(1):25. doi: 10.1186/s40959-025-00321-w.
2
Editorial: Case reports in cardio-oncology: 2022.社论:心血管肿瘤学病例报告:2022年
Front Cardiovasc Med. 2023 Jul 13;10:1235015. doi: 10.3389/fcvm.2023.1235015. eCollection 2023.
3
Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.嵌合抗原受体 T 细胞(CAR-T)疗法的心脏毒性:病理生理学、临床意义和超声心动图评估。
Int J Mol Sci. 2022 Jul 26;23(15):8242. doi: 10.3390/ijms23158242.
4
Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports.肿瘤学试验中的心血管不良事件:理解并认识临床试验数据与真实世界报告之间的差异
Cardiooncology. 2022 Jul 19;8(1):13. doi: 10.1186/s40959-022-00139-w.
5
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.BERENICE最终分析:新辅助帕妥珠单抗、曲妥珠单抗及化疗后序贯辅助帕妥珠单抗和曲妥珠单抗用于HER2阳性早期乳腺癌的心脏安全性研究
Cancers (Basel). 2022 May 24;14(11):2596. doi: 10.3390/cancers14112596.
6
Cardiac Safety of Osimertinib: A Review of Data.奥希替尼的心脏安全性:数据回顾。
J Clin Oncol. 2021 Feb 1;39(4):328-337. doi: 10.1200/JCO.20.01171. Epub 2020 Dec 23.
7
Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.曲妥珠单抗治疗的 HER2 阳性患者的心脏监测:综述及对临床实践的影响。
Breast. 2020 Aug;52:33-44. doi: 10.1016/j.breast.2020.04.005. Epub 2020 Apr 16.
8
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.曲妥珠单抗和/或拉帕替尼治疗优化试验中接受辅助治疗的 HER2 阳性乳腺癌患者的长期心脏结局。
Br J Cancer. 2020 May;122(10):1453-1460. doi: 10.1038/s41416-020-0786-x. Epub 2020 Mar 16.